REFERENCES
1. World Health Organization. Global report on diabetes. 2018. (date of access June 21, 2018)
2. International Diabetes Federation. IDF diabetes atlas. 8th ed. 2017. URL: http://www.diabetesatlas.org/across-the-globe.html (date of access June 21, 2018)
3. Fehse F., Trautmann M., Holst J.J., Halseth A.E., Nanayakkara N., Nielsen L.L., et al. Xenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 5991-7.
4. Meneghini L. New insulin preparations: a primer for the clinician. Cleve Clin J Med. 2016; 83 (5 suppl 1): S27-33.
5. Sanjay K., et al. Expert opinion: patient selection for premixed insulin formulations in diabetes care. Diabetes Ther. 2018; 9: 2185-99.
6. Harris S.B., Kapor J., Lank C.N., Willan A.R., Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010; 56: e418-24.
7. Dale J., Martin S., Gadsby R. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes. 2010; 4: 85-9.
8. Khunti K., Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017; 11: 3-12.
9. Billings L.K., et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL VII randomized clinical trial. Diabetes Care. 2018; 41 (5): 1009-16.
10. Seaquist E.R., Anderson J., Childs B., et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36: 1384-95.
11. Wenying Yang, et al. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: a phase III, open-label, 2:1 randomized, treat-to-target trial. Diabetes Obes Metab. 2019; 21: 1652-60.
12. Tevfik D., et al. Use of insulin degludec/insulin aspart in the management of diabetes mellitus: expert panel recommendations on appropriate practice patterns. Front Endocrinol. 2021; 12: 616514.
13. Havelund S., Ribel U., Hubalek F., Hoeg-Jensen T., Wahlund P.O., Jonassen I. Investigation of the physico-chemical properties that enable coformulation of basal insulin degludec with fast-acting insulin aspart. Pharm Res. 2015; 32: 2250-8. DOI: https://doi.org/10.1007/s11095-014-1614-x
14. Unnikrishnan A.G., Singh A.K., Modi K.D., Saboo B., Garcha S.C., Rao P.V. Review of clinical profile of IDegAsp. J Assoc Physicians India. 2015; 63: 15-20.
15. Haahr H., Fita E.G., Heise T. A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet. 2017; 56: 339-54. DOI: https://doi.org/10.1007/s40262-016-0455-7
16. Vaag A., Lund S.S. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012; 166: 159-70. DOI: https://doi.org/10.1530/EJE-11-0022
17. Dedov I.I., Shestakova M.V. Insulin degludec/insulin aspart is the first coformulation of basal and prandial insulin analogues. Sakharniy diabet [Diabetes Mellitus]. 2014; (4): 108-19. (in Russian)
18. Heise T., Tack C.J., Cuddihy R., et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011; 34 (3): 669-74.
19. Hirsch I.B., Franek E., Mersebach H., et al. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1). Diabet Med. 2017; 34 (2): 167-73.
20. Christiansen J.S., Niskanen L., Rasmussen S., et al. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two phase 3a studies in type 2 diabetes. J Diabetes. 2016; 8 (5): 720-8.
21. Hassanein M., Echtay A.S., Malek R., et al. Original paper: efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: a phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during. Diabetes Res Clin Pract. 2018; 135: 218-26.
22. Fulcher G., Mehta R., Fita E.G., et al. Efficacy and safety of IDegAsp versus BIAsp 30, both twice daily, in elderly patients with type 2 diabetes: post hoc analysis of two phase 3 randomized controlled BOOST trials. Diabetes Ther. 2019; 10 (1): 107-18.
23. Dedov I.I., Shestakova M.V., Mayorov A.Yu., et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (1S1): 144 p. (in Russian)
24. Shestakova M.V., Surkova E.V., Vachugova A.A., et al. The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists. Sakharniy diabet [Diabetes Mellitus]. 2021; 24 (2): 175-84. (in Russian)